ELEDON PHARMACEUTICALS INC (ELDN) Stock Price, Forecast & Analysis
NASDAQ:ELDN • US28617K1016
ELDN Key Statistics, Chart & Performance
The current stock price of ELDN is 2.22 USD. In the past month the price increased by 0.91%. In the past year, price decreased by -48.25%.
ELDN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ELDN. When comparing the yearly performance of all stocks, ELDN turns out to be only a medium performer in the overall market: it outperformed 45.78% of all stocks.
ELDN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELDN. While ELDN has a great health rating, there are worries on its profitability.
ELDN Financial Highlights
Over the last trailing twelve months ELDN reported a non-GAAP Earnings per Share(EPS) of 0.25. The EPS increased by 112.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.83% | ||
| ROE | -11.17% | ||
| Debt/Equity | 0 |
ELDN Forecast & Estimates
13 analysts have analysed ELDN and the average price target is 8.16 USD. This implies a price increase of 267.57% is expected in the next year compared to the current price of 2.22.
ELDN Ownership
ELDN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 404.235B | ||
| AMGN | AMGEN INC | 16.66 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.63 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.499B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ELDN
Company Profile
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Company Info
ELEDON PHARMACEUTICALS INC
19800 Macarthur Blvd., Suite 250
Irvine CALIFORNIA 92612 US
CEO: David-Alexandre C. Gros
Employees: 31
Phone: 19492388090
ELEDON PHARMACEUTICALS INC / ELDN FAQ
What does ELDN do?
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
What is the current price of ELDN stock?
The current stock price of ELDN is 2.22 USD. The price increased by 5.71% in the last trading session.
Does ELDN stock pay dividends?
ELDN does not pay a dividend.
How is the ChartMill rating for ELEDON PHARMACEUTICALS INC?
ELDN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for ELEDON PHARMACEUTICALS INC?
ELEDON PHARMACEUTICALS INC (ELDN) currently has 31 employees.
What is ELEDON PHARMACEUTICALS INC worth?
ELEDON PHARMACEUTICALS INC (ELDN) has a market capitalization of 175.91M USD. This makes ELDN a Micro Cap stock.
What is the next earnings date for ELDN stock?
ELEDON PHARMACEUTICALS INC (ELDN) will report earnings on 2026-03-18, after the market close.